ID: ALA1818436

Max Phase: Preclinical

Molecular Formula: C6H13NO3

Molecular Weight: 147.17

Molecule Type: Small molecule

Representations

Canonical SMILES:  OC[C@@H]1NCC[C@@H](O)[C@H]1O

Standard InChI:  InChI=1S/C6H13NO3/c8-3-4-6(10)5(9)1-2-7-4/h4-10H,1-3H2/t4-,5+,6-/m0/s1

Standard InChI Key:  YZNNBIPIQWYLDM-JKUQZMGJSA-N

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 147.17

Molecular Weight (Monoisotopic): 147.0895

AlogP: -1.94

#Rotatable Bonds: 1

Polar Surface Area: 72.72

Molecular Species: BASE

HBA: 4

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.43

CX Basic pKa: 8.63

CX LogP: -2.20

CX LogD: -3.45

Aromatic Rings: 0

Heavy Atoms: 10

QED Weighted: 0.35

Np Likeness Score: 2.96

References

1. Kato A, Miyauchi S, Kato N, Nash RJ, Yoshimura Y, Nakagome I, Hirono S, Takahata H, Adachi I..  (2011)  Docking and SAR studies of D- and L-isofagomine isomers as human β-glucocerebrosidase inhibitors.,  19  (11): [PMID:21546253] [10.1016/j.bmc.2011.04.011]

2. van den Berg RJ, Wennekes T, Ghisaidoobe A, Donker-Koopman WE, Strijland A, Boot RG, van der Marel GA, Aerts JM, Overkleeft HS..  (2011)  Assessment of partially deoxygenated deoxynojirimycin derivatives as glucosylceramide synthase inhibitors.,  2  (7): [PMID:24900342] [10.1021/ml200050s]

Source

Source(1):

• Scientific Literature